PledPharma AB (publ) Share Price Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
Sales 2024 * | 60.73M 5.72M 475M | Sales 2025 * | 514M 48.42M 4.02B | Capitalization | 2.31B 217M 18.03B |
---|---|---|---|---|---|
Net income 2024 * | -289M -27.2M -2.26B | Net income 2025 * | 125M 11.76M 977M | EV / Sales 2024 * | 35.2 x |
Net cash position 2024 * | 167M 15.73M 1.31B | Net cash position 2025 * | 226M 21.24M 1.76B | EV / Sales 2025 * | 4.04 x |
P/E ratio 2024 * |
-7.68
x | P/E ratio 2025 * |
14.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.24% |
Latest transcript on PledPharma AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 16/17/16 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 31/17/31 |
Chief Tech/Sci/R&D Officer | - | 05/22/05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mats Blom
CHM | Chairman | 59 | 01/21/01 |
Director/Board Member | 50 | 01/20/01 | |
Thomas Lönngren
BRD | Director/Board Member | 73 | 01/21/01 |
1st Jan change | Capi. | |
---|---|---|
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.16% | 21.78B | |
-9.26% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |